These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 39241084)

  • 1. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis.
    Verboven L; Callens S; Black J; Maartens G; Dooley KE; Potgieter S; Cartuyvels R; ; Laukens K; Warren RM; Van Rie A
    PLoS One; 2024; 19(9):e0306101. PubMed ID: 39241084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis.
    Verboven L; Callens S; Black J; Maartens G; Dooley KE; Potgieter S; Cartuyvels R; ; Laukens K; Warren RM; Van Rie A
    Res Sq; 2023 Feb; ():. PubMed ID: 36824956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.
    Dudnyk A; Hempel M; Lytvyniuk O; Liudkevych H; Matsera V; Nikitchenko T; Blyzniuk S; Molina-Moya B; Preyer R; Domínguez J
    Ther Adv Respir Dis; 2024; 18():17534666241249841. PubMed ID: 38817020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial.
    Van Rie A; De Vos E; Costa E; Verboven L; Ndebele F; Heupink TH; Abrams S; ; Fanampe B; Van der Spoel Van Dyk A; Charalambous S; Churchyard G; Warren R
    Trials; 2022 Oct; 23(1):864. PubMed ID: 36209235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study.
    Cox H; Goig GA; Salaam-Dreyer Z; Dippenaar A; Reuter A; Mohr-Holland E; Daniels J; Cudahy PGT; Nicol MP; Borrell S; Reinhard M; Doetsch A; Beisel C; Gagneux S; Warren RM; Furin J
    J Clin Microbiol; 2022 Mar; 60(3):e0236221. PubMed ID: 35170980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis.
    Verboven L; Calders T; Callens S; Black J; Maartens G; Dooley KE; Potgieter S; Warren RM; Laukens K; Van Rie A
    BMC Med Inform Decis Mak; 2022 Mar; 22(1):56. PubMed ID: 35236355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
    Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
    Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial.
    Demers AM; Kim S; McCallum S; Eisenach K; Hughes M; Naini L; Mendoza-Ticona A; Pradhan N; Narunsky K; Poongulali S; Badal-Faesen S; Upton C; Smith E; Shah NS; Churchyard G; Gupta A; Hesseling A; Swindells S;
    BMC Infect Dis; 2021 Feb; 21(1):205. PubMed ID: 33627075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.
    Bhanushali A; Atre S; Nair P; Thandaseery GA; Shah S; Kuruwa S; Zade A; Nikam C; Gomare M; Chatterjee A
    Microbiol Spectr; 2024 May; 12(5):e0277023. PubMed ID: 38597637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand.
    Prommi A; Wongjarit K; Petsong S; Somsukpiroh U; Faksri K; Kawkitinarong K; Payungporn S; Rotcheewaphan S
    Microbiol Spectr; 2024 Mar; 12(3):e0346223. PubMed ID: 38323824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
    Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G
    Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia.
    Vīksna A; Sadovska D; Berge I; Bogdanova I; Vaivode A; Freimane L; Norvaiša I; Ozere I; Ranka R
    BMC Infect Dis; 2023 Sep; 23(1):638. PubMed ID: 37770850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014-2018.
    Bahizi G; Majwala RK; Kisaka S; Nyombi A; Musisi K; Kwesiga B; Bulage L; Ario AR; Turyahabwe S
    Antimicrob Resist Infect Control; 2021 May; 10(1):76. PubMed ID: 33964986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.